Schistosoma infections remain a major public health issue mainly in tropical and subtropical regions. While Praziquantel is the primary treatment for schistosomiasis, its limitations include resistance development and poor efficacy against juvenile worms. Given the biological similarities between tumor and parasite-infected cells, LSD1 inhibitors─primarily explored as anticancer agents─have been investigated for their antiparasitic potential.
Tranylcypromine-Based LSD1 Inhibitors as Useful Agents to Reduce Viability of Schistosoma mansoni / Fabbrizi, Emanuele; Hailu, Gebremedhin Solomon; Ganesan, A.; Fioravanti, Rossella; Zwergel, Clemens; Lambona, Chiara; Valente, Sergio; Fianco, Giulia; Iuzzolino, Angela; Trisciuoglio, Daniela; Caroli, Jonatan; Mattevi, Andrea; Häberli, Cécile; Keiser, Jennifer; Rotili, Dante; Mai, Antonello. - In: ACS INFECTIOUS DISEASES. - ISSN 2373-8227. - 11:8(2025), pp. 2178-2189. [10.1021/acsinfecdis.5c00224]
Tranylcypromine-Based LSD1 Inhibitors as Useful Agents to Reduce Viability of Schistosoma mansoni
Fabbrizi, Emanuele;Hailu, Gebremedhin Solomon;Fioravanti, Rossella;Zwergel, Clemens;Lambona, Chiara;Valente, Sergio;Mai, Antonello
2025
Abstract
Schistosoma infections remain a major public health issue mainly in tropical and subtropical regions. While Praziquantel is the primary treatment for schistosomiasis, its limitations include resistance development and poor efficacy against juvenile worms. Given the biological similarities between tumor and parasite-infected cells, LSD1 inhibitors─primarily explored as anticancer agents─have been investigated for their antiparasitic potential.| File | Dimensione | Formato | |
|---|---|---|---|
|
Fabbrizi_supporting_Tranylcypromine-Based_2025.pdf
accesso aperto
Note: supporting information
Tipologia:
Altro materiale allegato
Licenza:
Creative commons
Dimensione
311.58 kB
Formato
Adobe PDF
|
311.58 kB | Adobe PDF | |
|
Fabbrizi_Tranylcypromine-Based_2025.pdf
accesso aperto
Note: articolo principale
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
2.19 MB
Formato
Adobe PDF
|
2.19 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
